Health Times of Rhode Island
SEE OTHER BRANDS

Your health and wellness news from Rhode Island

Health Times of Rhode Island: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.

Press releases published on September 3, 2025

American Botanical Council Debuts Saw Palmetto Educational Video on HerbTV

American Botanical Council Debuts Saw Palmetto Educational Video on HerbTV

Austin, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The nonprofit American Botanical Council (ABC) announces the premiere of its new educational video, “Saw Palmetto: Safe and Effective Herb for Prostate and Men’s Urinary Health.” The video is available on …

Clover Health CEO Andrew Toy Testifies Before Congress on the Transformative Role of AI in Healthcare, Highlights how Clover is Leading the Way

Clover Health CEO Andrew Toy Testifies Before Congress on the Transformative Role of AI in Healthcare, Highlights how Clover is Leading the Way

WASHINGTON, D.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) – Clover Health CEO Andrew Toy today had the honor to deliver testimony before the U.S. House of …

Banner Health honored for commitment to well-being of physicians

Banner Health honored for commitment to well-being of physicians

PHOENIX, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Banner Health has again earned prestigious recognition from American Medical Association (AMA) for the continued commitment to reducing burnout and promoting well-being among health care workers. This marks the …

New Study: Gut Health Program Cuts Infant Eczema Odds by 83% in C-Section Babies

New Study: Gut Health Program Cuts Infant Eczema Odds by 83% in C-Section Babies

AUSTIN, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- A new study found that babies born by C-section had 83% lower odds of developing eczema when their families participated in a 6-month gut health support program, compared to those who didn't receive the …

PharmaCorp to Acquire Two Pharmacies in Western Canada

PharmaCorp to Acquire Two Pharmacies in Western Canada

SASKATOON, Saskatchewan, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into definitive share purchase agreements, each dated August 29, 2025 (the “ …

Microbix Hosts Ontario Minister Stephen Crawford

Microbix Hosts Ontario Minister Stephen Crawford

MISSISSAUGA, Ontario, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces its hosting of the Honourable Stephen Crawford, Ontario’s Minister of …

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patients Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less …

PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight

PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight

New York, USA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight  The outlook for the PDE4B inhibitors market is changing as this drug class demonstrates significant therapeutic promise in respiratory …

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patients Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less …

AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem

AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem

AlphaTON Capital Unlocks Public Market Access to Toncoin (TON) and Telegram’s Billion-User Ecosystem Brittany Kaiser, pioneer in data protection, digital assets, and the public equity markets appointed Chief Executive Officer and Board Member Formerly …

Society for Science Recognizes Top 300 Middle School Innovators in Nation’s Premier STEM Competition

Society for Science Recognizes Top 300 Middle School Innovators in Nation’s Premier STEM Competition

WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Society for Science is proud to announce the Top 300 Junior Innovators in the 2025 Thermo Fisher Scientific Junior Innovators Challenge (Thermo Fisher JIC)—the nation’s premier science, technology, engineering …

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to topical steroids and vitamin-D analogs ZORYVE cream is …

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic …

Clinical Asset Management leader TRIMEDX adds to leadership team with key technology hire to accelerate innovation and AI strategy

Clinical Asset Management leader TRIMEDX adds to leadership team with key technology hire to accelerate innovation and AI strategy

Indianapolis, Indiana, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TRIMEDX—an industry-leading, independent clinical asset management company delivering comprehensive clinical engineering services, clinical asset informatics, and medical device cybersecurity—has …

Scenic Biotech Publishes Novel Drug Target for Mitochondrial and Cardiac Disease in Nature

Scenic Biotech Publishes Novel Drug Target for Mitochondrial and Cardiac Disease in Nature

Second Nature publication in 3 months highlights strength of Scenic’s proprietary Cell-Seq platform to identify modifier genes that positively influence disease severity Amsterdam, the Netherlands, September 03, 2025 – Scenic Biotech, a pioneer in the …

KFSHRC Reinforces Global Leadership as Early Adopter of Advanced cell and Gene Therapies

KFSHRC Reinforces Global Leadership as Early Adopter of Advanced cell and Gene Therapies

SAUDI ARABIA, Riyadh, Sept. 03, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital …

2025 Rising Stars to Take the Stage at BioNTX iC³® Life Science & Healthcare Innovation Summit

2025 Rising Stars to Take the Stage at BioNTX iC³® Life Science & Healthcare Innovation Summit

DALLAS, Sept. 03, 2025 (GLOBE NEWSWIRE) --  BioNTX has announced the 2025 Rising Stars, a select group of companies recognized for their bold contributions to life sciences and healthcare innovation. These trailblazing organizations will be formally …

Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System

Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient’s own platelets and plasma that, once applied, may assist the …

TeamACO reduces avoidable costs by $15.8M for Medicare value-based care program

TeamACO reduces avoidable costs by $15.8M for Medicare value-based care program

KNOXVILLE, Tenn., Sept. 03, 2025 (GLOBE NEWSWIRE) -- In its inaugural year, TeamACO, TeamHealth’s accountable care organization, serving nearly 15,000 post-acute care patients in 33 states, is proud to announce it reduced avoidable costs of care for …

AMA Announces 2025 Joy in Medicine Recognized Health Organizations

AMA Announces 2025 Joy in Medicine Recognized Health Organizations

CHICAGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The American Medical Association (AMA) today named 109 hospitals, health systems and medical groups that have earned national distinction in 2025 as Joy in Medicine® organizations. The prestigious recognition …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions